Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.55 |
| ▸ | ITK | Q08881 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CLK3 | P49761 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789205 | 0.88 | CYP19A1 (0.68) | CYP19A1KDM4ENPC1ALDH1A1HPGD | |
| Tert-Butyl Formate SCHEMBL28080870 | 0.87 | CYP19A1 (0.52) | CYP19A1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL21812408 | 0.84 | CYP19A1 (0.71) | CYP19A1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL31317820 | 0.84 | CYP19A1 (0.71) | CYP19A1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL1606072 | 0.83 | CYP19A1 (0.65) | CYP19A1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL7939806 | 0.82 | CYP19A1 (0.68) | CYP19A1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL1605652 | 0.82 | CYP19A1 (0.68) | CYP19A1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL1605882 | 0.82 | CYP19A1 (0.68) | CYP19A1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL1606556 | 0.82 | CYP19A1 (0.68) | CYP19A1MAPTITKIDO1CYP2A6 | |
| SCHEMBL1606084 | 0.81 | NPC1 (0.69) | CYP19A1KDM4ENPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074385-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3074385-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| CN-105793249-B | Piperidine derivatives for the treatment or prevention of psychiatric and neurological disorders | 武田药品工业株式会社 | 2019-09-24 | — | — | CN | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| EP-3074385-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-05 | — | — | EP | disclosed |
| CN-105793249-A | Piperidine derivatives for the treatment or prevention of psychiatric and neurological disorders | 武田药品工业株式会社 | 2016-07-20 | — | — | CN | disclosed |
| WO-2015079224-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015079224-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | GRIN2C, GRIN2A, PNMT | CYP19A1 1344/4885KDM4E 1727/4885NPC1 532/4885 |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | GRIN2C, GRIN2A, PNMT | CYP19A1 1344/4885KDM4E 1727/4885NPC1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.